{
    "ticker": "LEXX",
    "name": "Lexaria Bioscience Corp.",
    "description": "Lexaria Bioscience Corp. is a biotechnology company focused on the development of innovative drug delivery technologies. Founded in 2014, Lexaria aims to enhance the bioavailability and efficacy of various therapeutic compounds using its proprietary DehydraTECH technology. This technology allows for the oral delivery of lipophilic active pharmaceutical ingredients, improving absorption rates and achieving faster onset times compared to traditional delivery methods. Lexaria's research primarily targets cannabis-derived compounds and nicotine, presenting a significant potential in the growing markets of cannabinoid-based therapies and nicotine replacement products. The company's mission is to improve the delivery of active ingredients for better health outcomes and to develop innovative products that offer advantages over conventional formulations. With a commitment to safety and efficacy, Lexaria collaborates with various research institutions and industry partners to advance its product pipeline and research initiatives. The company is headquartered in Kelowna, British Columbia, Canada, and is publicly traded on the NASDAQ, showcasing its dedication to transparency and shareholder value.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Kelowna, British Columbia, Canada",
    "founded": "2014",
    "website": "https://www.lexariabioscience.com",
    "ceo": "Chris Bunka",
    "social_media": {
        "twitter": "https://twitter.com/LexariaBiosci",
        "linkedin": "https://www.linkedin.com/company/lexaria-bioscience-corp/"
    },
    "investor_relations": "https://www.lexariabioscience.com/investor-relations/",
    "key_executives": [
        {
            "name": "Chris Bunka",
            "position": "CEO"
        },
        {
            "name": "Cynthia M. Rinehart",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Cannabinoid Delivery",
            "products": [
                "Cannabinoid-infused products",
                "Pharmaceutical formulations"
            ]
        },
        {
            "category": "Nicotine Delivery",
            "products": [
                "Nicotine replacement therapies"
            ]
        }
    ],
    "seo": {
        "meta_title": "Lexaria Bioscience Corp. | Innovative Drug Delivery Technologies",
        "meta_description": "Explore Lexaria Bioscience Corp., a leader in drug delivery technology focused on enhancing the bioavailability of cannabinoids and nicotine for improved health outcomes.",
        "keywords": [
            "Lexaria",
            "Drug Delivery",
            "Biotechnology",
            "Cannabinoids",
            "Nicotine",
            "DehydraTECH"
        ]
    },
    "faq": [
        {
            "question": "What is Lexaria known for?",
            "answer": "Lexaria is known for its innovative drug delivery technology, DehydraTECH, which enhances the bioavailability of cannabinoids and nicotine."
        },
        {
            "question": "Who is the CEO of Lexaria?",
            "answer": "Chris Bunka is the CEO of Lexaria Bioscience Corp."
        },
        {
            "question": "Where is Lexaria headquartered?",
            "answer": "Lexaria is headquartered in Kelowna, British Columbia, Canada."
        },
        {
            "question": "What are Lexaria's main products?",
            "answer": "Lexaria's main products include cannabinoid-infused products and nicotine replacement therapies."
        },
        {
            "question": "When was Lexaria founded?",
            "answer": "Lexaria was founded in 2014."
        }
    ],
    "competitors": [
        "GWPH",
        "CVSI",
        "CURLF"
    ],
    "related_stocks": [
        "APHA",
        "TLRY",
        "CRON",
        "CARA"
    ]
}